QDRO
← Ingredients

Surfactant · Cocamidopropyl Betaine · CAS 61789-40-0

Cocamidopropyl Betaine (CAPB)

Cocamidopropyl betaine (CAPB) is an amphoteric surfactant derived from coconut oil, used in toothpaste as a milder alternative to SLS. Clinical studies confirm it causes significantly less mucosal irritation and fewer aphthous ulcers at working concentrations of 1–2%. QDRO uses it as the primary surfactant across the entire product line.

QDRO position

We use it

Amphoteric surfactant instead of SLS — mild safety profile confirmed by regulatory bodies and clinical data.

Effective concentration

1–3%

Typical on market: 1–2%

Cocamidopropyl Betaine (CAPB)

What It Is

Cocamidopropyl betaine (CAPB) is a synthetic amphoteric surfactant produced from coconut oil fatty acids. Despite the "coconut" origin, CAPB is not a natural extract: coconut fatty acids are reacted with dimethylaminopropylamine and chloroacetic acid, forming a molecule with a characteristic betaine group — an internal salt with a quaternary nitrogen and a carboxylate.

This zwitterionic structure is the key to CAPB's profile: at acidic pH it behaves as a cationic surfactant, at alkaline pH as anionic, and at neutral pH (the typical oral environment) it carries no net charge. The broad pH stability and dual-charge character distinguish it from purely anionic detergents like SLS.

CAPB entered oral care formulations at scale around 2008, driven by accumulating clinical evidence that SLS causes measurable mucosal damage in a significant proportion of users.

How It Works

Foaming Mechanism

CAPB lowers the surface tension of the aqueous phase in toothpaste, allowing air to disperse as a stable, fine-bubble foam. This foam physically distributes the paste across tooth surfaces and soft tissues, suspends plaque and debris, and facilitates rinsing. CAPB foam is less voluminous than SLS foam — a sensory difference, not a functional one.

Interaction with Oral Epithelium

Anionic surfactants such as SLS insert into the lipid bilayer of epithelial cell membranes and disrupt intercellular junctions (desmosomes), leading to desquamation of the mucosal surface. CAPB, as a zwitterion at oral pH, lacks the sustained ionic interaction with negatively charged membrane components that drives this damage.

In a double-blind crossover study (Herlofson & Barkvoll, 1996, PMID: 8653493), 28 healthy women used seven toothpaste formulas — SLS at 0.5%, 1.0%, 1.5%; CAPB at 0.64%, 1.27%, 1.90%; and a detergent-free placebo — via custom trays for four days. SLS caused dose-dependent desquamation significantly exceeding all three CAPB concentrations.

Compatibility with Active Ingredients

CAPB is compatible with both anionic and cationic compounds, a property anionic surfactants cannot offer. This makes it uniquely suited for formulas combining foaming agents with cationic actives such as cetylpyridinium chloride, chlorhexidine, or zinc salts — none of which survive co-formulation with SLS at meaningful concentrations.

Clinical Evidence

Aphthous Ulcer Frequency

The most clinically relevant trial compared SLS, CAPB, and a detergent-free paste in 30 patients with frequent recurrent aphthous ulcers over three 6-week crossover periods (Herlofson & Barkvoll, 1996, PMID: 8811135). Ulcer frequency was significantly higher with SLS. The difference between CAPB and the detergent-free placebo was not statistically significant — meaning CAPB did not provoke additional ulcers.

For patients prone to aphthous stomatitis, replacing SLS with CAPB is itself a therapeutic intervention, not merely a formulation preference.

Safety Review (CIR, 2012 and 2024)

The Cosmetic Ingredient Review Expert Panel evaluated CAPB comprehensively in 2012 and again in 2024 (PMID: 38911545). Key findings from the 2024 assessment: NOAEL of 250 mg/kg/day from a 92-day oral rat study; estimated systemic exposure during typical cosmetic use: 0.0012–0.93 mg/kg/day — a safety margin exceeding 270-fold. Conclusion: CAPB is safe as a cosmetic ingredient when formulated to be non-sensitizing.

What Does Not Work

  • CAPB has no intrinsic antibacterial activity. It does not substitute for antiseptic actives.
  • CAPB does not enhance bioavailability of fluoride, hydroxyapatite, or other actives — its role is purely mechanical distribution and rinsing.
  • At concentrations above 2%, experimental models still recorded measurable mucosal irritation, though substantially less than SLS equivalents.

Safety

Allergy: Impurities, Not CAPB Itself

Most allergic reactions attributed to CAPB in patch-test studies are caused by manufacturing impurities — primarily amidoamine and dimethylaminopropylamine (DMAPA), not the CAPB molecule itself. A study by Corazza et al. (PMID: 15573642) found positive patch reactions to CAPB or amidoamine in approximately 5% of tested patients. Modern purification standards reduce impurity levels to analytically insignificant amounts, substantially lowering the allergenic potential of high-grade CAPB.

Emerging Signal: Plasma Cell Gingivitis

A 2025 case series (PMID: 40133141) described a possible association between CAPB-containing toothpastes and plasma cell gingivitis — a rare inflammatory gingival condition historically linked to flavoring agents. This is a case series, not a controlled trial; causation has not been established. Symptom resolution in some patients following CAPB removal has been noted. This represents an observational signal warranting follow-up research, not a basis for classifying CAPB as unsafe.

Comparison with Alternatives

| Feature | SLS | CAPB | Sodium Cocoamphoacetate | |---|---|---|---| | Charge type | Anionic | Amphoteric (zwitterion) | Amphoteric | | Foam volume | High | Moderate, creamy | Moderate | | Mucosal irritation | High (dose-dependent) | Low | Very low | | Aphthous ulcer risk | Elevated | Neutral | Neutral | | Compatible with cationic actives | No | Yes | Yes | | Allergenic potential | Low | Low (with pure raw material) | Low | | Typical concentration in paste | 0.5–2% | 1–2% | 1–3% |

QDRO Position

QDRO does not use SLS in any formula. The primary surfactant system across the line is CAPB combined with sodium cocoamphoacetate. This combination delivers the necessary foaming and cleansing action without compromising the mucosal barrier or competing with actives — nano-hydroxyapatite, xylitol, and zinc citrate.

We monitor emerging data, including the plasma cell gingivitis signal, and will revise our formulations if systematic evidence of causation emerges.

Sources:

  • Herlofson BB, Barkvoll P. (1996). The effect of two toothpaste detergents on the frequency of recurrent aphthous ulcers. Acta Odontol Scand. PMID: 8811135
  • Herlofson BB, Barkvoll P. (1996). Oral mucosal desquamation caused by two toothpaste detergents in an experimental model. Eur J Oral Sci. PMID: 8653493
  • Burnett CL et al. (2012). Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Cocamidopropyl Betaine (CAPB). Int J Toxicol.
  • Safety assessment of cocamidopropyl betaine, a cosmetic ingredient. (2024). PMID: 38911545
  • Saku S et al. (2025). Cocamidopropyl betaine: another possible oral healthcare chemical associated with plasma cell lesions of the oral cavity. PMID: 40133141
  • Corazza M et al. (2004). Relevance of positive patch-test reactions to cocamidopropyl betaine and amidoamine. Contact Dermatitis. PMID: 15573642